Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

148 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clonal hematopoiesis of indeterminate potential in the companion dog.
Sebastian K, Özer HG, Howard C, Chadsey L, Lozanski A, Doong TJ, Orwick S, Lozanski G, Ma W, Kisseberth WC, Byrd JC, Harrington BK. Sebastian K, et al. Among authors: lozanski a, lozanski g. Leukemia. 2022 May;36(5):1401-1403. doi: 10.1038/s41375-022-01520-5. Epub 2022 Feb 10. Leukemia. 2022. PMID: 35145204 No abstract available.
Adult Burkitt leukemia and lymphoma.
Blum KA, Lozanski G, Byrd JC. Blum KA, et al. Among authors: lozanski g. Blood. 2004 Nov 15;104(10):3009-20. doi: 10.1182/blood-2004-02-0405. Epub 2004 Jul 20. Blood. 2004. PMID: 15265787 Free article. Review.
Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
Byrd JC, Gribben JG, Peterson BL, Grever MR, Lozanski G, Lucas DM, Lampson B, Larson RA, Caligiuri MA, Heerema NA. Byrd JC, et al. Among authors: lozanski g. J Clin Oncol. 2006 Jan 20;24(3):437-43. doi: 10.1200/JCO.2005.03.1021. Epub 2005 Dec 12. J Clin Oncol. 2006. PMID: 16344317
Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia.
Byrd JC, Lin TS, Dalton JT, Wu D, Phelps MA, Fischer B, Moran M, Blum KA, Rovin B, Brooker-McEldowney M, Broering S, Schaaf LJ, Johnson AJ, Lucas DM, Heerema NA, Lozanski G, Young DC, Suarez JR, Colevas AD, Grever MR. Byrd JC, et al. Among authors: lozanski g. Blood. 2007 Jan 15;109(2):399-404. doi: 10.1182/blood-2006-05-020735. Epub 2006 Sep 26. Blood. 2007. PMID: 17003373 Free PMC article. Clinical Trial.
Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia.
Blum W, Klisovic RB, Hackanson B, Liu Z, Liu S, Devine H, Vukosavljevic T, Huynh L, Lozanski G, Kefauver C, Plass C, Devine SM, Heerema NA, Murgo A, Chan KK, Grever MR, Byrd JC, Marcucci G. Blum W, et al. Among authors: lozanski g. J Clin Oncol. 2007 Sep 1;25(25):3884-91. doi: 10.1200/JCO.2006.09.4169. Epub 2007 Aug 6. J Clin Oncol. 2007. PMID: 17679729 Clinical Trial.
A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents.
Lapalombella R, Zhao X, Triantafillou G, Yu B, Jin Y, Lozanski G, Cheney C, Heerema N, Jarjoura D, Lehman A, Lee LJ, Marcucci G, Lee RJ, Caligiuri MA, Muthusamy N, Byrd JC. Lapalombella R, et al. Among authors: lozanski g. Clin Cancer Res. 2008 Jan 15;14(2):569-78. doi: 10.1158/1078-0432.CCR-07-1006. Clin Cancer Res. 2008. PMID: 18223233
Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia.
Andritsos LA, Johnson AJ, Lozanski G, Blum W, Kefauver C, Awan F, Smith LL, Lapalombella R, May SE, Raymond CA, Wang DS, Knight RD, Ruppert AS, Lehman A, Jarjoura D, Chen CS, Byrd JC. Andritsos LA, et al. Among authors: lozanski g. J Clin Oncol. 2008 May 20;26(15):2519-25. doi: 10.1200/JCO.2007.13.9709. Epub 2008 Apr 21. J Clin Oncol. 2008. PMID: 18427150 Free PMC article.
Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells.
Lapalombella R, Yu B, Triantafillou G, Liu Q, Butchar JP, Lozanski G, Ramanunni A, Smith LL, Blum W, Andritsos L, Wang DS, Lehman A, Chen CS, Johnson AJ, Marcucci G, Lee RJ, Lee LJ, Tridandapani S, Muthusamy N, Byrd JC. Lapalombella R, et al. Among authors: lozanski g. Blood. 2008 Dec 15;112(13):5180-9. doi: 10.1182/blood-2008-01-133108. Epub 2008 Sep 4. Blood. 2008. PMID: 18772452 Free PMC article.
Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab.
Awan FT, Kay NE, Davis ME, Wu W, Geyer SM, Leung N, Jelinek DF, Tschumper RC, Secreto CR, Lin TS, Grever MR, Shanafelt TD, Zent CS, Call TG, Heerema NA, Lozanski G, Byrd JC, Lucas DM. Awan FT, et al. Among authors: lozanski g. Blood. 2009 Jan 15;113(3):535-7. doi: 10.1182/blood-2008-08-173450. Epub 2008 Nov 13. Blood. 2009. PMID: 19008456 Free PMC article. Clinical Trial.
148 results